CFR Pharmaceuticals

Credit Suisse on Monday upgraded Abbott Laboratories (NYSE: ABT) to Outperform from Neutral following the company's announcement to acquire CFR Pharmaceuticals SA and raised the price target to $46 from $44. Credit Suisse analyst Bruce Nudell says the acquisition, which has an estimated value of $...